Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus long levofloxacin-rifampicin therapy for staphylococcal prosthetic joint infection
ISRCTN35285839Phase 4Completed
- Sponsor
- Bellvitge University Hospital
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levofloxacin and rifampicin in periprosthetic joint infection (PJI) and Staphylococcal periprosthetic joint infection (SPJI) (2 arms), sponsored by Bellvitge University Hospital. Primary endpoint: Primary efficacy endpoint. Started Apr 2009; status: completed.
02
Drugs
levofloxacinrifampicin
03
Conditions
periprosthetic joint infection (PJI)Staphylococcal periprosthetic joint infection (SPJI)
Beyond the preview
Go deeper on ISRCTN35285839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35285839.